Search Results - "Wilhelm, Bram"

An effective modestly intensive re‐induction regimen with bortezomib in relapsed or refractory paediatric acute lymphoblastic leukaemia by Kaspers, Gertjan J. L., Niewerth, Denise, Wilhelm, Bram A. J., Scholte‐van Houtem, Peggy, Lopez‐Yurda, Marta, Berkhof, Johannes, Cloos, Jacqueline, de Haas, Valerie, Mathôt, Ron A., Attarbaschi, Andishe, Baruchel, André, de Bont, Eveline S., Fagioli, Franca, Rössig, Claudia, Klingebiel, Thomas, De Moerloose, Barbara, Nelken, Brigitte, Palumbo, Giuseppe, Reinhardt, Dirk, Rohrlich, Pierre‐Simon, Simon, Pauline, Stackelberg, Arend, Zwaan, Christian Michel

“…Summary This trial explored the efficacy of re‐induction chemotherapy including bortezomib in paediatric relapsed/refractory acute lymphoblastic leukaemia…”
Get full text

Predicting treatment response to vancomycin using bacterial DNA load as a pharmacodynamic marker in premature and very low birth weight neonates: A population PKPD study by Samb, Amadou, De Kroon, Rimke, Dijkstra, Koos, Van Den Brand, Marre, Bos, Martine, Van Den Dungen, Frank, Veldkamp, Agnes, Wilhelm, Bram, De Haan, Timo R, Bijleveld, Yuma A, Tutu Van Furth, Marceline, Savelkoul, Paul, Swart, Noortje, Mathot, Ron, Van Weissenbruch, Mirjam

“…While positive blood cultures are the gold standard for late-onset sepsis (LOS) diagnosis in premature and very low birth weight (VLBW) newborns, these results…”
Get full text

Phase II Study on Bortezomib (BTZ) in Multiple Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (rALL): High Response Rate with a Modestly Intensive Regimen Including BTZ, Not Related to Pharmacokinetics by Kaspers, Gertjan J.L., Niewerth, Denise, Wilhelm, Bram, Ramnarain, Satianand, Berkhof, Hans, De Haas, Valerie, Mathôt, Ron A.A., Attarbaschi, Andishe, Baruchel, Andre, de Bont, Eveline S., Fagioli, Franca, Rossig, Claudia, Klingebiel, Thomas, De Moerloose, Barbara, Nelken, Brigitte, Palumbo, Giuseppe, Reinhardt, Dirk, Rohrlich, Pierre Simon, Simon, Pauline, Stackelberg, Arend, Zwaan, C. Michel

“…BTZ is a proteasome inhibitor and could improve the poor prognosis of rALL (Messinger 2012). We developed a European phase II study in pediatric rALL, in which…”
Get full text

S1238 Levels of 6-Thioguanine Nucleotides Following Oral and Intravenous Administration of Relatively Low-Dosed 6-TG (0,3 mg/kg) in IBD-Patients by Jharap, Bindia, de Boer, Nanne, Vos, René M, Peters, Godefridus J, Wilhelm, Bram, Mulder, Chris J, van Bodegraven, Ad A

Get full text

Safety and Biodistribution of 99mTechnetium-labeled Anti-CD44v6 Monoclonal Antibody BIWA 1 in Head and Neck Cancer Patients by STROOMER, J. W. G, ROOS, J. C, ADOLF, G. R, VAN DONGEN, G. A. M. S, SPROLL, M, QUAK, J. J, HEIDER, K.-H, WILHELM, B. J, CASTELIJNS, J. A, MEYER, R, KWAKKELSTEIN, M. O, SNOW, G. B

“…The CD44 protein family consists of isoforms, encoded by standard exons and up to nine alternatively spliced variant exons (v2–v10), which are expressed in a…”
Get full text